ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,160,000 shares, a growth of 5.4% from the October 15th total of 2,050,000 shares. Based on an average daily volume of 310,500 shares, the short-interest ratio is currently 7.0 days.

ANI Pharmaceuticals Stock Down 4.0 %

ANIP traded down $2.33 during trading on Friday, reaching $56.58. 293,055 shares of the company were exchanged, compared to its average volume of 270,423. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a 50 day moving average of $58.40 and a 200 day moving average of $61.31. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. During the same quarter in the previous year, the business posted $1.05 EPS. The business's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, equities research analysts expect that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ANIP. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a report on Wednesday, September 18th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 22nd. StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.33.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANIP. Pacer Advisors Inc. grew its holdings in shares of ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock valued at $33,907,000 after acquiring an additional 565,910 shares in the last quarter. Bank of Montreal Can bought a new stake in ANI Pharmaceuticals in the 3rd quarter valued at about $13,043,000. Millennium Management LLC grew its position in ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock worth $14,651,000 after buying an additional 209,272 shares in the last quarter. Mizuho Markets Americas LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter worth $11,670,000. Finally, Barclays PLC raised its position in shares of ANI Pharmaceuticals by 1,681.2% in the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after buying an additional 135,003 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.